David E. I. Pyott
CIK: 0001051578
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Sep 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Indirect201 shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
806 shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
2.4K shares- - Jun 1, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct3.8K shares- - Jun 1, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct921 shares at avg. $297.71$274K - Jun 1, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $298.91$351K - Jun 1, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $299.87$366K - Jun 1, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct495 shares at avg. $300.72$149K - Jun 1, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct17 shares at avg. $302.65$5K - May 20, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct671 shares- - Apr 24, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct1.4K shares- - Feb 18, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
3.7K shares- - Feb 18, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
5.9K shares- - Jun 5, 2025PLRX
PLIANT THERAPEUTICS, INC.
Award(A)DirectCommon Stock (Right to Buy)
30K shares- - May 8, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct775 shares- - Mar 24, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct7.4K shares at avg. $299.00$2.2M - Mar 24, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct7.4K shares at avg. $88.95$662K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 15, 2026 |  TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 201 | - | $0 | Indirect |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 806 | - | - | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,837 | - | - | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,417 | - | - | Direct |
| Jun 1, 2026 |  ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 3,830 | - | $0 | Direct |
| Jun 1, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 921 | $297.71 | $274,191 | Direct |
| Jun 1, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,175 | $298.91 | $351,219 | Direct |
| Jun 1, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,222 | $299.87 | $366,441 | Direct |
| Jun 1, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 495 | $300.72 | $148,856 | Direct |
| Jun 1, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 17 | $302.65 | $5,145 | Direct |
| May 20, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 671 | - | $0 | Direct |
| Apr 24, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 1,383 | - | $0 | Direct |
| Feb 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 3,729 | - | - | Direct |
| Feb 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 5,893 | - | - | Direct |
| Jun 5, 2025 |  PLRX PLIANT THERAPEUTICS, INC. | Award(A) Common Stock (Right to Buy) | 30,000 | - | - | Direct |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 775 | - | - | Direct |
| Mar 24, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 7,440 | $299.00 | $2,224,560 | Direct |
| Mar 24, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 7,440 | $88.95 | $661,788 | Direct |
1-18 of 18 transactions
About PYOTT DAVID E I
PYOTT DAVID E I (SEC CIK 0001051578) files insider reports with the SEC as Director of Tarsus Pharmaceuticals, Inc. (TARS), Director of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and Director of PLIANT THERAPEUTICS, INC. (PLRX).
Signal8 holds 10 ownership filings by PYOTT DAVID E I (1 Form 3, 9 Form 4), filed between Mar 25, 2025 and Sep 17, 2026. Those filings report 18 transactions, from Mar 24, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on PYOTT DAVID E I's filings is in IRVINE, CA.
Recent filings by PYOTT DAVID E I
- Sep 15, 2026: Option exercise of TARS shares (Form 4, code M).
- Jun 25, 2026: Grants or awards of TARS derivative securities (3 lines, Form 4, code A).
- Jun 1, 2026: Option exercise of ALNY shares (Form 4, code M).
- Jun 1, 2026: Open-market sales of ALNY shares (5 lines, Form 4, code S).
- May 20, 2026: Grant or award of ALNY shares (Form 4, code A).
Other insiders filing for Tarsus Pharmaceuticals, Inc. (TARS)
- YARNO WENDY L, Director
- LINK WILLIAM J PHD, Director
- Azamian Bobak R., President/CEO and Board Chair
- Lin Elizabeth Yeu, Chief Medical Officer
- Neervannan Seshadri, Chief Operating Officer
- Goodrich Katherine, Director